| Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19 L Naymagon, N Zubizarreta, J Feld, M van Gerwen, M Alsen, S Thibaud, ... Thrombosis research 196, 99-105, 2020 | 157 | 2020 |
| Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study D Tremblay, M Van Gerwen, M Alsen, S Thibaud, A Kessler, S Venugopal, ... Blood, The Journal of the American Society of Hematology 136 (1), 144-147, 2020 | 151 | 2020 |
| Ferritin levels in patients with COVID‐19: a poor predictor of mortality and hemophagocytic lymphohistiocytosis J Feld, D Tremblay, S Thibaud, A Kessler, L Naymagon International journal of laboratory hematology 42 (6), 773-779, 2020 | 100 | 2020 |
| Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19 S Thibaud, D Tremblay, S Bhalla, B Zimmerman, K Sigel, J Gabrilove British journal of haematology 190 (2), e73, 2020 | 88 | 2020 |
| Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ... Blood 141 (7), 756-765, 2023 | 53 | 2023 |
| Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma TH Mouhieddine, O Van Oekelen, DT Melnekoff, J Li, Y Ghodke-Puranik, ... Blood advances 7 (6), 1056-1064, 2023 | 29 | 2023 |
| Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies G Lancman, K Parsa, C Rodriguez, J Richter, HJ Cho, S Parekh, ... Blood 140 (Supplement 1), 10073-10074, 2022 | 29 | 2022 |
| IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies G Lancman, K Parsa, K Kotlarz, L Avery, A Lurie, A Lieberman-Cribbin, ... Blood Cancer Discovery 4 (6), 440-451, 2023 | 20 | 2023 |
| Comprehensive characterization of prolonged unexplained cytopenias in relapsed/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy S Thibaud, MB Mia, O Van Oekelen, TH Mouhieddine, C Schaniel, ... Blood 140 (Supplement 1), 614-616, 2022 | 20 | 2022 |
| POEMS syndrome: real world experience in diagnosis and systemic therapy-108 patients multicenter analysis A Jurczyszyn, JJ Castillo, M Olszewska-Szopa, L Kumar, S Thibaud, ... Clinical Lymphoma Myeloma and Leukemia 22 (5), 297-304, 2022 | 19 | 2022 |
| HIV portends a poor prognosis in myelodysplastic syndromes JD Kaner, S Thibaud, S Jasra, Y Wang, M Janakiram, A Sharma, ... Leukemia & lymphoma 60 (14), 3529-3535, 2019 | 19 | 2019 |
| Therapeutic potential of isatuximab in the treatment of multiple myeloma: evidence to date J Richter, L Sanchez, S Thibaud Seminars in Oncology 47 (2-3), 155-164, 2020 | 16 | 2020 |
| Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19 G Lancman, BK Marcellino, S Thibaud, K Troy Annals of Hematology 100, 833-835, 2021 | 12 | 2021 |
| Association between neutrophil–lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma Y Zhang, NP Brodin, N Ohri, S Thibaud, A Kaubisch, M Kinkhabwala, ... Hepatology International 13, 609-617, 2019 | 10 | 2019 |
| Timing and nature of infections in multiple myeloma patients treated with anti-BCMA CAR-T cells G Lancman, M Shyu, M Metzger, K Parsa, HJ Cho, S Parekh, J Richter, ... Blood 140 (Supplement 1), 7198-7199, 2022 | 5 | 2022 |
| HIV is associated with a high rate of unexplained multilineage cytopenias and portends a poor prognosis in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) J Kaner, S Thibaud, A Sridharan, A Assal, R Polineni, B Zingman, ... Blood 128 (22), 4345, 2016 | 5 | 2016 |
| Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups UA Shah, E Moshier, A Derkach, Y Huang, S Mailankody, CR Tan, ... Blood Advances 8 (1), 236-247, 2024 | 3 | 2024 |
| Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease D Pan, TH Mouhieddine, W Fu, E Moshier, S Parekh, S Jagannath, ... Blood 142, 1006, 2023 | 3 | 2023 |
| Anti-body building: The exercise of advancing immune based myeloma therapies J Richter, S Thibaud Blood Reviews 48, 100789, 2021 | 3 | 2021 |
| Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in … JV dos Santos, D Melnekoff, A Aleman, S Bhalla, TH Mouhieddine, ... Blood 142, 93, 2023 | 2 | 2023 |
Joshua RichterAssociate Professor, Tisch Cancer Institute: Icahn School of Medicine at Mount Sinai在 mountsinai.org 的电子邮件经过验证
